Cargando…

PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA

Detalles Bibliográficos
Autores principales:	Li, S., Wen, S.-J., Ma, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429078/ http://dx.doi.org/10.1097/01.HS9.0000851152.49123.64

Ejemplares similares

PB2080: LOW DUP1 EXPRESSION PREDICTS POOR PROGNOSIS IN MULTIPLE MYELOMA
por: Lu, Jinfeng, et al.
Publicado: (2023)

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2105: REAL WORLD EXPERIENCE WITH POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR R/R DLBCL IN 3 ACADEMIC CENTERS IN MADRID, SPAIN.
por: Corrochano, M., et al.
Publicado: (2022)

PB2274: REAL-WORLD OUTCOME OF FOLLICULAR LYMPHOMA IN TAIWAN: A MULTICENTER REGISTRY STUDY
por: Ko, Bor-Sheng, et al.
Publicado: (2023)

PB2084: FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.
por: Mompel, O., et al.
Publicado: (2022)

PB2399: BRENTUXIMAB VEDOTIN IN TREATING CHINESE PATIENTS WITH LYMPHOMA:A MULTICENTER,REAL-WORLD STUDY
por: Zhang, Xudong, et al.
Publicado: (2023)

PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS’ ERA
por: Cerchione, C., et al.
Publicado: (2022)

PB2284: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC ASPECT OF INDOLENT LYMPHOMAS IN TUNISIA
por: Charef, Ons, et al.
Publicado: (2023)

PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS
por: Duell, J., et al.
Publicado: (2022)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
por: Kallel, F., et al.
Publicado: (2022)

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009)

PB2062: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF REFRACTORY HODGKIN’S LYMPHOMA.
por: Ben Sghaier, R., et al.
Publicado: (2022)

PB2435: ALLOGENEIC STEM CELL TRANSPLANTATION OUTCOMES IN HODGKIN LYMPHOMA: A PROGNOSTIC STUDY OF 30 PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
por: Zamani, Shayan, et al.
Publicado: (2023)

PB2256: EPIDEMIOLOGY AND OUTCOMES OF HODGKIN LYMPHOMA IN URUGUAY. A NATIONAL REGISTRY
por: Oliver, Carolina, et al.
Publicado: (2023)

Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
por: Pezzullo, Luca, et al.
Publicado: (2021)

PB2282: HERPESVIRUSES REPLICATION DURING COVID-19 IN NON-HODGKIN’S LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

PB2383: MICROSATELLITE INSTABILITY AND 9P24.1 ALTERATIONS IN HODGKIN LYMPHOMA
por: Tregubova, Ekaterina, et al.
Publicado: (2023)

PB2321: THE EFFECT OF PRE-TREATMENT SERUM KINDLIN-3 ON HODGKIN AND NON-HODGKIN LYMPHOMAS: A SINGLE CENTER EXPERIENCE
por: Keskin, Melike, et al.
Publicado: (2023)

PB1880: A MULTICENTER PHASE 1 STUDY EVALUATING THE SAFETY AND TOLERABILITY OF HMPL-760 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR OTHER NON-HODGKIN LYMPHOMA
por: Kahl, B., et al.
Publicado: (2022)

PB2255: ASSESSMENT OF CHEMOTHERAPY-INDUCED TOXICITY IN CHILDREN WITH HODGKIN LYMPHOMA RECEIVING THE EURONET PROTOCOL
por: Bekhit, Hala, et al.
Publicado: (2023)

PB2402: CLINICAL CHARACTERISTICSAND PROGNOSIS RISK FACTORS OF NON-HODGKIN’S LYMPHOMA INVOLVING THE HEART
por: Chen, Yue, et al.
Publicado: (2023)

Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011)

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
por: Weide, Rudolf
Publicado: (2008)

PB2306: REAL-WORLD FIRST-LINE TREATMENT AND OUTCOMES AMONG PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH STANDARD OF CARE
por: Yan, Jiali, et al.
Publicado: (2023)

PB2063: CHARACTERISTICS AND THERAPEUTIC RESULTS OF PATIENTS WITH REFRACTORY/RELAPSED HODGKIN LYMPHOMA IN A TUNISIAN CENTER
por: Kammoun, F., et al.
Publicado: (2022)

PB2360: HIV-ASSOCIATED BURKITT LYMPHOMA IN THE COMBINATION ANTIRETROVIRAL THERAPY ERA: REAL-WORLD OUTCOMES AND PROGNOSTICATION
por: Wang, Chaoyu, et al.
Publicado: (2023)

PB2065: IMPORTANCE OF PET AS A PROGNOSTIC MARKER IN TREATMENT STRATEGY CHOICE IN PATIENTS WITH HODGKIN LYMPHOMA
por: Novosad, O., et al.
Publicado: (2022)

PB2257: OUTCOME AND PROGNOSTIC FACTORS OF PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE
por: Ali, Nesreen, et al.
Publicado: (2023)

PB2254: TREATMENT OUTCOME AND PROGNOSTIC FACTORS IN CHILDREN AND ADOLESCENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ali, Nesreen, et al.
Publicado: (2023)

PB2316: SAFETY AND EFFICACY OF AUTOLOGOUS HSCT IN NINE PATIENTS WITH AIDS-RELATED NON-HODGKIN LYMPHOMA
por: Liu, Jun, et al.
Publicado: (2023)

PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES
por: Hirano, Mitsuhito, et al.
Publicado: (2023)

PB2106: REAL-WORLD SAFETY AND EFFECTIVENESS OF SELINEXOR-BASED REGIMENS IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT RENAL IMPAIRMENT
por: Niblock, James, et al.
Publicado: (2023)

PB2320: FIRST LINE THERAPY FOR DIFFUSE LARGE B CELL LYMPHOMA AMONG THE ELDERLY: A TUNISIAN MULTICENTER EXPERIENCE.
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2156: ANALYSIS OF POSSIBLE CLONAL ORIGIN OF LARGE B-CELL DIFFUSED LYMPHOMAS ARISING IN PATIENTS WITH PRE-EXISTING HODGKIN’S LYMPHOMA
por: Masciopinto, P., et al.
Publicado: (2022)

PB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIAL
por: Wang, H., et al.
Publicado: (2022)

PB2066: THE STUDY OF GSTP1 AND MDR1 GENES POLYMORPHISMS IN HODGKIN’S LYMPHOMA AND THEIR LINK WITH CHEMOTHERAPY RESPONSE.
por: Voytko, M., et al.
Publicado: (2022)

PB2322: MULTIPLE PRIMARY TUMORS IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER STUDY
por: Sahakyan, Lusine, et al.
Publicado: (2023)

PB2415: THE ROLE OF NUTRITIONAL SUPPORT DURING AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTOHSCT) IN PATIENTS WITH HODGKIN LYMPHOMA.
por: Volchenkov, Stanislav, et al.
Publicado: (2023)

PB2259: THE NEW PD-1 INHIBITOR PROLGOLIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
por: Semenova, Anastasia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v6u6s6pv8oqg1d8dl8jdjnhl6d